RecruitingNCT04025515
Molecular Profiling Project
ATORG001 - Molecular Profiling Project
Sponsor
National Cancer Centre, Singapore
Enrollment
500 participants
Start Date
Jan 11, 2019
Study Type
OBSERVATIONAL
Conditions
Summary
In this study, the investigators plan to undertake comprehensive molecular profiling of "actionable" alterations in lung cancer specimens in order to determine the prevalence of each genetic subtype in the local population.
Eligibility
Min Age: 21 Years
Plain Language Summary
Simplified for easier understanding
This study is performing detailed molecular profiling — analyzing the genetic and molecular makeup — of tumor samples from cancer patients to identify potential targets for clinical trials and personalized treatment strategies.
**You may be eligible if...**
- You are 21 or older
- You have enough stored tumor tissue available for molecular testing (at least 15 slides)
- You are in adequate health overall (WHO performance status ≤ 2, life expectancy ≥ 12 weeks)
- Your blood counts, liver function, and other organ tests meet minimum thresholds
- You are willing to provide signed informed consent
**You may NOT be eligible if...**
- There is insufficient tumor tissue for testing
- You are too unwell to potentially participate in future clinical trials
- You have conditions that compromise your organ function to a degree that would exclude you from most trials
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04025515
Related Trials
Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)
NCT066944541 location
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760229 locations
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
NCT06345729216 locations
Evaluation for NCI Surgery Branch Clinical Research Protocols
NCT000018231 location
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
NCT06692738301 locations